

September 24, 2020 COM-2020-070

RECALL NOTIFICATION



FDA PUBLICATION DATE: September 23, 2020

DRUG NAME: RIOMET ER™

COMPANY: Sun Pharmaceutical Industries, Inc.

REASON: Due to detection of N-Nitrosodimethylamine (NDMA) Impurity

Dear provider of pharmaceutical services,

PharmPix is committed to the health and wellness of our members. The clinical team wants to communicate you with the latest up-to-date information on drug safety. It is for this reason, that we are notifying you that on September 23, 2020, the US Food and Drug Administration (FDA) published a voluntary recall for one lot of RIOMET ER™ (metformin hydrochloride for extended-release oral suspension) manufactured by Sun Pharmaceutical Industries (also known as SUN PHARMA).

| Product | NDC | Lot Number | Ехр. |
|---------------|--------------|------------|---------|
| | | | date |
| RIOMET ER™ | 10631-019-17 | AB06381 | 10/2021 |
| (500mg/ 5 mL) | | | |

The voluntary recall is due to the detection of N-Nitrosodimethylamine (NDMA) impurity above the allowable Acceptable Daily Intake (ADI) limit. NDMA is a compound classified as a probable carcinogen to the human population. Patients taking RIOMET ER™ should continue taking it and contact their physician for advice regarding an alternative treatment.

Pharmacy required actions(s):

• Identify if the product is inventory and immediately stop using and dispensing it. The product should be returning to the place of purchase or as directed in the recall notification.

urac



- Advise patients that they should not discontinue using the medication without contacting their healthcare provider for guidance or a replacement prescription.
- For further information: Contact SUN PHARMA by calling 1-800-818-4555 or e-mailing drug.safetyUSA@sunpharma.com for the questions about the recalled product. SUN PHARMA will notify distributors and customers through Inmar, Inc. (a recall coordinator) to arrange the returns.

Contact information:

Remember, you can report adverse events or side effects at <u>MedWatch: The FDA Safety</u>

<u>Information and Adverse Event Reporting Program</u> by any of the following ways:

- Complete and submit the <u>MedWatch Online Voluntary Reporting Form</u> online.
- <u>Download</u> the FDA Form 3500 or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form or submit by fax to 1-800-FDA-0178.

Additional information can be found at:

- FDA Recall for RIOMET ER
- MedWatch: The FDA Safety Information and Adverse Event Reporting Program

If you have any questions or wish to have more information regarding this document, you can call us at 787-522-5252, extension 137. In addition, know that you can access our recent communications at our providers' portal: https://www.pharmpix.com/providers/.

Regards,

PharmPix Clinical Department

Reference(s):

U.S. Food and Drug Administration. (2020). Sun Pharmaceutical Industries, Inc. Issues Voluntary Nationwide Recall of RIOMET ER™ (Metformin hydrochloride for Extended-Release oral suspension) due to N-Nitrosodimethylamine (NDMA) content above the Acceptable Daily Intake (ADI) limit. Retrieved September 24, 2020 from https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sun-pharmaceutical-industries-inc-issues-voluntary-nationwide-recall-riomet-ertm-

metformin#:~:text=(SUN%20PHARMA)%2C%20a%20wholly,mL%20to%20the%20consumer%20level.&text=To%20date%2C%20SUN%20PHARMA A%20has,events%20related%20to%20this%20recall.